MRKR - Marker Therapeutics completes safety lead-in portion of mid-stage leukemia study

Marker Therapeutics (MRKR) announces completion of the six-patient safety lead-in portion of the company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia ((AML)).The multicenter mid-stage study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting.The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients.Marker said that it is currently enrolling patients in the main portion of its trial and continues to activate clinical sites across the U.S. Shares up more than 4% premarket.

For further details see:

Marker Therapeutics completes safety lead-in portion of mid-stage leukemia study